Hematoporphyrin monomethyl ether-mediated photodynamic effects on THP-1 cell-derived macrophages

Journal of Photochemistry and Photobiology B: Biology

Volumn 101, Issue 1, 2010, Pages 9-15

  Cheng, Jiali ^a   Liang, Huijuan ^b   Li, Qingsong ^a   Peng, Chenghai ^a   Li, Zhitao ^a   Shi, Sa ^a   Yang, Liming ^a   Tian, Zhen ^a   Tian, Ye ^a   Zhang, Zhiguo ^b   Cao, Wenwu ^b,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN INSTITUTE OF TECHNOLOGY   (China)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; HMME; Macrophage; PDT

Indexed keywords

CASPASE 3; CASPASE 9; HEMATOPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN METHYL ETHER; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL STRAIN; CELL STRAIN THP 1; CELL SURVIVAL; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIODE LASER; DRUG ACCUMULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MACROPHAGE; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRIORITY JOURNAL; SURVIVAL RATE;

APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; FLOW CYTOMETRY; HEMATOPORPHYRINS; HUMANS; MACROPHAGES; MICROSCOPY, ELECTRON; MONOCYTES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PLAQUE, ATHEROSCLEROTIC;

EID: 77955659092     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2010.06.005     Document Type: Article

References (42)

1. Hellings W.E., Peeters W., Moll F.L., Pasterkamp G. From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc. Med. 2007, 17:162-171.
2. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8:1235-1242.
3. Choudhury R.P., Lee J.M., Greaves D.R. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat. Clin. Prac. Cardiovasc. Med. 2005, 2:309-315.
4. Huynh K.K., Gershenzon E., Grinstein S. Cholesterol accumulation by macrophages impairs phagosome maturation. J. Biol. Chem. 2008, 51:35745-35755.
5. Clarke M.C.H., Bennett M.R. Cause or consequence. What does macrophage apoptosis do in atherosclerosis?. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1262-1275.
6. Waksman R., McEwan P.E., Moore T.I., Pakala R., Kolodgie F.D., Hellinga D.G., Seabron R.C., Rychnovsky S.J., Vasek J., Scott R.W., Virmani R. PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression. J. Am. Cell. Cardiol. 2008, 52:1024-1032.
7. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 2009, 340:115-126.
8. Gordon T., Shigeyo H., John S., Steven G. Application of photodynamic therapy to the treatment of atherosclerotic plaques. Neurosurgery 1993, 32:438-443.
9. Jenkins M., Buonaccorsi G., Mansfield R., Bishop C., Bowna S., McEwanb J. Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid. Cardiovasc. Res. 2000, 45:478-485.
10. Hayase M., Woodbum K.W., Perlroth J., Miller R.A., Baumgardner W., Yock P.G., Yeung A. Photoangioplasty with local motexafin lutetium delivery reduces macrophages in a rabbit post-balloon injury model. Cardiovasc. Res. 2001, 49:449-455.
11. Rockson S.G., Lorenz D.P., Cheong W.F., Woodburn K.W. Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy. Circulation 2000, 102:591-596.
12. Chen Z., Woodburn K.W., Shi C., Adelman D.C., Rogers C., Simon D.I. Photodynamic therapy with Motexafin Lutetium induces redox-sensitive apoptosis of vascular cells. Arterioscler. Thromb. Vasc. Biol. 2001, 21:759-764.
13. Li P., Sun J., Huang C., Pan G., Xu M., Li J., Wang G., Tao J. Development and validation of a sensitive quantification method for hematoporphyrin monomethyl ether in plasma using high-performance liquid chromatography with fluorescence detection. Biomed. Chromatogr. 2006, 20:1277-1282.
14. Song K., Kong B., Qu X., Li L., Yang Q. Phototoxicity of hemoporfin to ovarian cancer. Biochem. Biophys. Res. Commun. 2005, 337:127-132.
15. Ding X., Xu Q., Liu F., Zhou P., Gu Y., Zeng J., An J., Dai W., Li X. Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation. Cancer Lett. 2004, 216:43-54.
16. Gu Y., Huang N.Y., Liang J., Pan Y.M., Liu F.G. Clinical study of 1949 cases of port wine stains treated with vascular photodynamic therapy (Gu's PDT). Ann. Dermatol. Venereol. 2007, 134:241-244.
17. Yuan K.H., Li Q., Yu W.L., Zeng D., Zhang C., Huang Z. Comparison of photodynamic therapy and pulsed dye laser in patients with port wine stain birthmarks: a retrospective analysis. Photodiagnosis Photodyn. Ther. 2008, 5:50-57.
18. Li C.Z., Cheng L.F., Wang Z.Q., Gu Y. Attempt of photodynamic therapy on esophageal varices. Lasers Med. Sci. 2009, 24:167-171.
19. 2 prevents foam cell formation by reducing scavenger receptor a expression in human macrophages. Circulation 2008, 118:2174-2182.
20. Tawakol A., Castano A.P., Gad F., Zahra T., Bashian G., Migrino R.Q., Ahmadi A., Stern J., Anatelli F., Chirico S., Shirazi A., Syed S., Fischman A.J., Muller J.E., Hamblin M.R. Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor. Photochem. Photobiol. Sci. 2008, 7:33-39.
21. Pai M., Jamal W., Mosse A., Bishop C., Bown S., McEwan J. Inhibition of in-stent restenosis in rabbit iliac arteries with photodynamic therapy. Eur. J. Vasc. Endovasc. Surg. 2005, 30:573-581.
22. Huang Z. A review of progress in clinical photodynamic therapy. Technol. Cancer Res. Treat. 2005, 4:283-293.
23. Fisher A.M.R., Murphree A.L., Gomer C.J. Clinical and preclinical photodynamic therapy. Lasers Surg. Med. 1995, 17:2-31.
24. Hamblin M.R., Miller J.L., Ortel B. Scavenger-receptor targeted photodynamic therapy. Photochem. Photobiol. 2000, 72:533-540.
25. Brasseur N., Langlois R., Madeleine C.L., Ouellet R., Lier J.E. Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Photochem. Photobiol. 1999, 69:345-352.
26. Vries H.E.D., Moor A.C.E., Dubbelman T.M.A.R., Berkel T.J.C.V., Kuiper J. Oxidized low-density lipoprotein as a delivery system for photosensitizers: implications for photodynamic therapy of atherosclerosis. J. Pharmacol. Exp. Ther. 1999, 289:528-534.
27. Juillerat-Jeanneret L., Schmitt F. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med. Res. Rev. 2007, 27:574-590.
28. Bordi F., Sennato S., Truzzolillo D. Polyelectrolyte-induced aggregation of liposomes: a new cluster phase with interesting applications. J. Phys.: Condens. Matter. 2009, 21:203102. (26pp).
29. Bordi F., Cametti C., Sennato S., Diociaiuti M. Direct evidence of multicompartment aggregates in polyelectrolyte-charged liposome complexes. Biophys. J. 2006, 91:1513-1520.
30. Volodkin D., Ball V., Schaaf P., Voegel J., Mohwald H. Complexation of phosphocholine liposomes with polylysine. Stabilization by surface coverage versus aggregation. Biochim. Biophys. Acta 2007, 1768:280-290.
31. Gautier E.L., Huby T., Witztum J.L., Ouzilleau B., Miller E.R., Charles F.S., Aucouturier P., Chapman M.J., Lesnik P. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009, 119:1795-1804.
32. Magaraggia M., Visona A., Furlan A., Pagnan A., Miotto G., Tognon G., Jori G. Inactivation of vascular smooth muscle cells photosensitized by liposome-delivered Zn (II)-phthalocyanine. J. Photochem. Photobiol. B: Biol. 2006, 8:253-258.
33. Granville D.J., Cassidy B.A., Ruehlmann D.O., Choy J.C., Brenner C., Kroemer G., Breemen C., Margaron P., Hunt D.W., McManus B.M. Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis. Am. J. Pathol. 2001, 159:305-311.
34. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S.A., Petit P.X., Mignotte B., Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J. Exp. Med. 1995, 182:367-377.
35. Kossodo S., LaMuraglia G.M. Clinical potential of photodynamic therapy in cardiovascular disorders. Am. J. Cardiovasc. Drugs 2001, 11:5-21.
36. Jenkins M.P., Buonaccorsi G.A., Raphael M., Nyamekye I., McEwan J.R., Bown S.G., Bishop C.C. Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty. Br. J. Surg. 1999, 86:258-263.
37. Gabeler E.E., Van Hillegersberg R., Sluiter W., Kliffen M., Statius van Eps R.G., Honkoop J., Carlier S.G., vanUrk H. Arterial wall strength after endovascular photodynamic therapy. Lasers Surg. Med. 2003, 33:8-15.
38. 2-induced oxidative stress result in different patterns of cellular protein oxidation. Eur. J. Biochem. 2003, 270:4859-4865.
39. Waterman P.R., Overhaus M., Heckenkamp J., Nigri G.R., Fungaloi P.F.C., Landis M.E., Kossodo S.C., LaMuraglia G.M. Mechanisms of reduced human vascular cell migration after photodynamic therapy. Photochem. Photobiol. 2002, 75:46-50.
40. Heckenkamp J., Aleksic M., Gawenda M., Breuer S., Brabender J., Mahdavi A., Aydin F., Brunkwall J.S. Modulation of human adventitial fibroblast function by photodynamic therapy of collagen matrix. Eur. J. Vasc. Endovasc. Surg. 2004, 28:651-659.
41. Satius E.R., LaMuraglia G. Photodynamic therapy inhibits transforming growth factor beta. J. Vasc. Surg. 1997, 26:1044-1052.
42. LaMuraglia G., Adili F., Karp S., Statius R.G., Watkins M.T. Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: insights into effects on the vascular wall. J. Vasc. Surg. 1997, 26:294-301.